Skip to content
Screener

Replimune Group REPL Shares (Diluted)

Shares (Diluted) at other companies

Amgen logo
AmgenAMGN
544M+0.6%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
106M-2.4%
Candel Therapeutics, Inc. logo
Candel Therapeutics, Inc.CADL
62.4M+13.9%
Regenxbio logo
RegenxbioRGNX
53M+3.0%
Immunome logo
ImmunomeIMNM
113.3M+30.2%
CG Oncology logo
CG OncologyCGON
88.2M+15.7%

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$1.01B+195%
Enterprise value$967.91M+199%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The source filing: Replimune Group’s 10-Q, filed February 3, 2026.

Filed
Feb 3, 2026, 8:12 AM EST
Fiscal quarter
Q3 FY2026
Calendar quarter
Q4 2025
Accession
0001628280-26-004805
Line itemThree Months Ended December 31, 2025Three Months Ended December 31, 2024Nine Months Ended December 31, 2025Nine Months Ended December 31, 2024
Interest expense on debt obligations(1,466)(1,450)(4,429)(4,314)
Other (expense) income, net(580)(3,281)(865)(850)
Total other income (expense), net6272545,5479,707
Loss before income taxes$(71,241)$(65,765)$(241,034)$(172,592)
Income tax (benefit) provision(311)$575$(311)$575
Net loss$(70,930)$(66,340)$(240,723)$(173,167)
Net loss per common share, basic and diluted$(0.77)$(0.79)$(2.62)$(2.25)
Weighted average common shares outstanding, basic and diluted92,187,58183,498,89291,874,48177,113,695

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Replimune Group's shares (diluted)?
Replimune Group (REPL) reported shares (diluted) of 92.2M in Q4 2025.
How has Replimune Group's shares (diluted) changed year-over-year?
Replimune Group's shares (diluted) increased by 10.4% year-over-year, from 83.5M to 92.2M.
What is the long-term trend for Replimune Group's shares (diluted)?
Over 3 years (2022 to 2025), Replimune Group's shares (diluted) has grown at a 14.4% compound annual growth rate (CAGR), from 208.5M to 311.8M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.

Ask your AI about Replimune Group's shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude